Abstract
Clinical characteristics to predict the development of coronary artery abnormalities (CAA) in Kawasaki disease (KD) were assessed by reviewing medical records of patients diagnosed with KD at Korea University Medical Center from March 2001 to February 2005. Of the 285 patients diagnosed with KD, 19 developed CAA (6.7%). Compared with the CAA(−) group, the CAA(+) group had a longer duration of fever after intravenous gamma-globulin (IVGG) injection (2.4±2.9 vs. 1.5±1.2 days, p=0.008) and higher C-reactive protein (CRP)(12.3±7.8 vs. 8.7±7.1 mg/dL, p=0.038). In particular, the CAA(+) group tended to have more than 7 days of fever before IVGG and more than 3 days of fever after IVGG (26.3 vs. 5.3%, p<0.001; 26.3 vs. 6.4%, p=0.002). When the IVGG responsiveness was defined by the presence of defervescence within 3 days after IVGG, IVGG-non-responders showed a higher incidence of CAA (22.7 vs. 5.3%, p=0.002). Non-responders had a longer duration of fever after IVGG (5.5±1.9 vs. 1.2±0.6 days, p<0.001) and a significantly increased CRP, AST, ALT and total bilirubin. Multivariate regression analysis for CAA showed that the only factor significantly associated with the development of CAA was total fever that lasted for longer than 8 days (OR=4.052, 95% CI=1.151–14.263, p=0.0293). Conclusively, the most important predictor of CAA in KD is total duration of fever longer than 8 days. Early identification of IVGG non-responders and active therapeutic intervention for fever in KD cases might decrease the incidence of CAA.
Similar content being viewed by others
Abbreviations
- KD:
-
Kawasaki disease
- IVGG:
-
intravenous gamma-globulin
- CAA:
-
coronary artery abnormalities
- CRP:
-
C-reactive protein
- BNP:
-
B-type natriuretic peptide
References
Burns JC, Capparelli EV, Brown JA, Newburger JW, Glode MP (1998) Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group. Pediatr Infect Dis J 17(12):1144–1148
Council on Cardiovascular Disease in the Young, Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, American Heart Association (2001) Diagnostic Guidelines for Kawasaki disease. Circulation 103(2):335–336
Durongpisitkul K, Soongswang J, Laohaprasitiporn D, Nana A, Prachuabmoh C, Kangkagate C (2003) Immunoglobulin failure and retreatment in Kawasaki disease. Pediatr Cardiol 24(2):145–148
Falcini F (2006) Kawasaki disease. Curr Opin Rheumatol 18(1):33–38
Fujiwara T, Fujiwara H, Nakano H (1988) Pathological features of coronary arteries in children with Kawasaki disease in which coronary arterial aneurysm was absent at autopsy. Quantitative analysis. Circulation 78(2):345–350
Fukunishi M, Kikkawa M, Hamana K, Onodera T, Matsuzaki K, Matsumoto Y, Hara J (2000) Prediction of non-responsiveness to intravenous high-dose gamma-globulin therapy in patients with Kawasaki disease at onset. J Pediatr 137(2):172–176
Harada K (1991) Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatr Jpn 33(6):805–810
Honkanen VE, McCrindle BW, Laxer RM, Feldman BM, Schneider R, Silverman ED (2003) Clinical relevance of the risk factors for coronary artery inflammation in Kawasaki disease. Pediatr Cardiol 24(2):122–126
Kawamura T, Wago M, Kawaguchi H, Tahara M, Yuge M (2000) Plasma brain natriuretic peptide concentrations in patients with Kawasaki disease. Pediatr Int 42(3):241–248
Kurotobi S, Nagai T, Kawakami N, Sano T (2002) Coronary diameter in normal infants, children and patients with Kawasaki disease. Pediatr Int 44(1):1–4
Kurotobi S, Kawakami N, Shimizu K, Aoki H, Nasuno S, Takahashi K, Kogaki S, Ozono K (2005) Brain natriuretic peptide as a hormonal marker of ventricular diastolic dysfunction in children with Kawasaki disease. Pediatr Cardiol 26(4):425–430
Miura M, Ohki H, Tsuchihashi T, Yamagishi H, Katada Y, Yamada K, Yamashita Y, Sugaya A, Komiyama O, Shiro H (2004) Coronary risk factors in Kawasaki disease treated with additional gammaglobulin. Arch Dis Child 89(8):776–780
Mori M, Imagawa T, Yasui K, Kanaya A, Yokota S (2000) Predictors of coronary artery lesions after intravenous gamma-globulin treatment in Kawasaki disease. J Pediatr 137(2):177–180
Muta H, Ishii M, Egami K, Furui J, Sugahara Y, Akagi T, Nakamura Y, Yanagawa H, Matsuishi T (2004) Early intravenous gamma-globulin treatment for Kawasaki disease: the nationwide surveys in Japan. J Pediatr 144(4):496–499
Muta H, Ishii M, Furui J, Nakamura Y, Matsuishi T (2006) Risk factors associated with the need for additional intravenous gamma-globulin therapy for Kawasaki disease. Acta Paediatr 95(2):189–193
Nakamura Y, Oki I, Tanihara S, Ojima T, Yanagawa H (1998) Cardiac sequelae in recurrent cases of Kawasaki disease: a comparison between the initial episode of the disease and a recurrence in the same patients. Pediatrics 102(6):E66
Nakamura Y, Yashiro M, Uehara R, Watanabe M, Tajimi M, Oki I, Ojima T, Sonobe T, Yanagawa H (2004) Use of laboratory data to identify risk factors of giant coronary aneurysms due to Kawasaki disease. Pediatr Int 46(1):33–38
Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, Shulman ST, Bolger AF, Ferrieri P, Baltimore RS, Wilson WR, Baddour LM, Levison ME, Pallasch TJ, Falace DA, Taubert K (2004) A Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young. American Heart Association. Circulation 110(17):2747–2771
Noto N, Okada T, Yamasuge M, Taniguchi K, Karasawa K, Ayusawa M, Sumitomo N, Harada K (2001) Noninvasive assessment of the early progression of atherosclerosis in adolescents with Kawasaki disease and coronary artery lesions. Pediatrics 107(5):1095–1099
Oki I, Tanihara S, Ojima T, Nakamura Y, Yanagawa H (2000) A multicenter collaborative study on the risk factors of cardiac sequelae due to Kawasaki disease: a one-year follow-up study. Acta Paediatr 89(12):1435–1438
Research Committee on Kawasaki Disease, Ministry of Health and Welfare, Tokyo (1984) Report of subcommittee on standardization of diagnostic criteria and reporting of coronary artery lesions in Kawasaki disease
Sasaguri Y, Kato H (1982) Regression of aneurysms in Kawasaki disease: a pathological study. J Pediatr 100(2):225–231
Shulman ST, Rowley AH (2004) Advances in Kawasaki disease. Eur J Pediatr 163(6):285–291
Silva AA, Maeno Y, Hashmi A, Smallhorn JF, Silverman ED, McCrindle BW (2001) Cardiovascular risk factors after Kawasaki disease: a case-control study. J Pediatr 138(3):400–405
Takahashi M, Mason W, Lewis AB (1987) Regression of coronary aneurysms in patients with Kawasaki syndrome. Circulation 75(2):387–394
de Zorzi A, Colan SD, Gauvreau K, Baker AL, Sundel RP, Newburger JW (1998) Coronary artery dimensions may be misclassified as normal in Kawasaki disease. J Pediatr 133(2):254–258
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kim, T., Choi, W., Woo, CW. et al. Predictive risk factors for coronary artery abnormalities in Kawasaki disease. Eur J Pediatr 166, 421–425 (2007). https://doi.org/10.1007/s00431-006-0251-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00431-006-0251-8